MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-01-2025
Blueprint Medicines Corporation Market Cap 2011-2026 | BPMC
As of April 14, 2026 Blueprint Medicines Corporation has a market cap of $ 8.14 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.96 B | 5.31 B | 2.66 B | 6.27 B | 6.12 B | 3.07 B | 3.11 B | 3.06 B | 913 M | 287 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.27 B | 287 M | 3.67 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 8.64 | 8.07 % | $ 85.4 M |  USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 3.11 | 5.42 % | $ 265 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cabaletta Bio
CABA
|
283 M | $ 3.2 | 2.24 % | $ 322 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 21.36 | 4.86 % | $ 998 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
101 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.47 | 5.0 % | $ 378 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 2.92 | - | $ 4.81 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.19 | 2.7 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 24.12 | -0.37 % | $ 3.07 B | USA |
 |
Chimerix
CMRX
|
104 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
103 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.47 | -1.34 % | $ 391 M | Britain |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | USA |
 |
CNS Pharmaceuticals
CNSP
|
1.06 M | $ 2.44 | 11.7 % | $ 1.08 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 4.25 | 8.35 % | $ 286 B | Britain |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |